|
1
|
Chen WQ, Zuo TT, Zheng RS, Zeng HM, Zhang
SW and He J: Lung cancer incidence and mortality in China in 2013.
Zhonghua Zhong Liu Za Zhi. 39:795–800. 2017.(In Chinese).
PubMed/NCBI
|
|
2
|
Wang X and Adjei AA: Lung cancer and
metastasis: New opportunities and challenges. Cancer Metastasis
Rev. 34:169–171. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Riihimäki M, Hemminki A, Fallah M, Thomsen
H, Sundquist K, Sundquist J and Hemminki K: Metastatic sites and
survival in lung cancer. Lung Cancer. 86:78–84. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yan X, Jiao SC, Zhang GQ, Guan Y and Wang
JL: Tumor-associated immune factors are associated with recurrence
and metastasis in non-small cell lung cancer. Cancer Gene Ther.
24:57–63. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wan J and Wu W: Hyperthermia induced
HIF-1α expression of lung cancer through AKT and ERK signaling
pathways. J Exp Clin Cancer Res. 35:1192016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhou H, Chen A, Shen J, Zhang X, Hou M, Li
J, Chen J, Zou H, Zhang Y, Deng Q, et al: Long non-coding RNA
LOC285194 functions as a tumor suppressor by targeting p53 in
non-small celllung cancer. Oncol Rep. 41:15–26. 2019.PubMed/NCBI
|
|
7
|
Sasaki M, Sugio K, Kuwabara Y, Koga H,
Nakagawa M, Chen T, Kaneko K, Hayashi K, Shioyama Y, Sakai S and
Honda H: Alterations of tumor suppressor genes (Rb, p16, p27 and
p53) and an increased FDG uptake in lung cancer. Ann Nucl Med.
17:189–196. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lee TG, Jeong EH, Kim SY, Kim HR, Kim H
and Kim CH: Fhit, a tumor suppressor protein, induces autophagy via
14-3-3τ in non-small cell lung cancer cells. Oncotarget.
8:31923–31937. 2017.PubMed/NCBI
|
|
9
|
Wang H, Ye L, Xing Z, Li H, Lv T, Liu H,
Zhang F and Song Y: CDCA7 promotes lung adenocarcinoma
proliferation via regulating the cell cycle. Pathol Res Pract.
215:1525592019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Qian X, Song X, He Y, Yang Z, Sun T, Wang
J, Zhu G, Xing W and You C: CCNB2 overexpression is a poor
prognostic biomarker in Chinese NSCLC patients. Biomed
Pharmacother. 74:222–227. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Duan J, Huang W and Shi H: Positive
expression of KIF20A indicates poor prognosis of glioma patients.
Onco Targets Ther. 9:6741–6749. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
E L, Lu L, Li L, Yang H, Schwartz LH and
Zhao B: Radiomics for classification of lung cancer histological
subtypes based on nonenhanced computed tomography. Acad Radiol.
26:1245–1252. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yeo MK, Choi SY, Seong IO, Suh KS, Kim JM
and Kim KH: Association of PD-L1 expression and PD-L1 gene
polymorphism with poor prognosis in lung adenocarcinoma and
squamous cell carcinoma. Hum Pathol. 68:103–111. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Haga A, Takahashi W, Aoki S, Nawa K,
Yamashita H, Abe O and Nakagawa K: Classification of early stage
non-small cell lung cancers on computed tomographic images into
histological types using radiomic features: Interobserver
delineation variability analysis. Radiol Phys Technol. 11:27–35.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lee G, Lee HY, Park H, Schiebler ML, van
Beek EJR, Ohno Y, Seo JB and Leung A: Radiomics and its emerging
role in lung cancer research, imaging biomarkers and clinical
management: State of the art. Eur J Radiol. 86:297–307. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shen R, Olshen AB and Ladanyi M:
Integrative clustering of multiple genomic data types using a joint
latent variable model with application to breast and lung cancer
subtype analysis. Bioinformatics. 25:2906–2912. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cui H, Seubert B, Stahl E, Dietz H,
Reuning U, Moreno-Leon L, Ilie M, Hofman P, Nagase H, Mari B and
Kruger A: Tissue inhibitor of metalloproteinases-1 induces a
pro-tumourigenic increase of miR-210 in lung adenocarcinoma cells
and their exosomes. Oncogene. 34:3640–3650. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Person RJ, Tokar EJ, Xu Y, Orihuela R,
Ngalame NN and Waalkes MP: Chronic cadmium exposure in vitro
induces cancer cell characteristics in human lung cells. Toxicol
Appl Pharmacol. 273:281–288. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Goda N, Dozier SJ and Johnson RS: HIF-1 in
cell cycle regulation, apoptosis, and tumor progression. Antioxid
Redox Signal. 5:467–473. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wan J, Chai H, Yu Z, Ge W, Kang N, Xia W
and Che Y: HIF-1α effects on angiogenic potential in human small
cell lung carcinoma. J Exp Clin Cancer Res. 30:772011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lee CH, Lee MK, Kang CD, Kim YD, Park DY,
Kim JY, Sol MY and Suh KS: Differential expression of hypoxia
inducible factor-1 alpha and tumor cell proliferation between
squamous cell carcinomas and adenocarcinomas among operable
Non-small cell lung carcinomas. J Korean Med Sci. 18:196–203. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang H, Zhang Z, Xu Y, Xing L, Liu J, Li
J and Tan Q: The expression of hypoxia inducible factor 1-alpha in
lung cancer and its correlation with P53 and VEGF. J Huazhong Univ
Sci Technolog Med Sci. 24:124–127. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Khan MN, Haggag YA, Lane ME, McCarron PA
and Tambuwala MM: Polymeric Nano-encapsulation of curcumin enhances
its anti-cancer activity in breast (MDA-MB231) and lung (A549)
cancer cells through reduction in expression of HIF-1α and nuclear
p65 (Rel A). Curr Drug Deliv. 15:286–295. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jun W and Jian W: Current progression of
radiofrequency ablation (RFA) in clinical application of lung
cancer therapy. J Biomater Tissue Eng. 9:417–426. 2019. View Article : Google Scholar
|
|
25
|
Luo W, Zhou P and Li W: Advances in
diagnosis and treatment of multiple primary lung cancer. Zhongguo
Fei Ai Za Zhi. 18:640–643. 2015.(In Chinese). PubMed/NCBI
|
|
26
|
de Baère T, Aupérin A, Deschamps F,
Chevallier P, Gaubert Y, Boige V, Fonck M, Escudier B and
Palussiére J: Radiofrequency ablation is a valid treatment option
for lung metastases: Experience in 566 patients with 1037
metastases. Ann Oncol. 26:987–991. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hiraki T, Gobara H, Iguchi T, Fujiwara H,
Matsui Y and Kanazawa S: Radiofrequency ablation for early-stage
nonsmall cell lung cancer. Biomed Res Int. 2014:1520872014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Qi H and Fan W: Value of ablation therapy
in the treatment of lung metastases. Thorac Cancer. 9:199–207.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li G, Xue M, Chen W and Yi S: Efficacy and
safety of radiofrequency ablation for lung cancers: A systematic
review and meta-analysis. Eur J Radiol. 100:92–98. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu B, Ye X, Fan W, Li X, Feng W, Lu Q,
Mao Y, Lin Z, Li L, Zhuang Y, et al: Expert consensus for
image-guided radiofrequency ablation of pulmonary tumors (2018
version). Zhongguo Fei Ai Za Zhi. 21:76–88. 2018.(In Chinese).
PubMed/NCBI
|
|
31
|
Palussière J, Catena V and Buy X:
Percutaneous thermal ablation of lung tumors-Radiofrequency,
microwave and cryotherapy: Where are we going? Diagn Interv
Imaging. 98:619–625. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yamamoto A, Hamamoto S, Matsuoka T,
Kageyama K, Jogo A, Sohgawa E, Okuma T, Hamuro M, Toyoshima M,
Kawabe J, et al: Spontaneous regression of untreated tumors with
immuno-radiofrequency ablation, RF ablation in combination with
local injection of OK-432, in a patient with lung metastases of
colon cancer. J Vasc Interv Radiol. 28:477–479. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wan J, Wu W and Zhang RQ: Local recurrence
of small cell lung cancer following radiofrequency ablation is
induced by HIF-1α expression in the transition zone. Oncol Rep.
35:1297–1308. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lin CS, Liu TC, Lee MT, Yang SF and Tsao
TC: Independent prognostic value of hypoxia-inducible factor
1-alpha expression in small cell lung cancer. Int J Med Sci.
14:785–790. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shin JW, Cho DG, Choi SY, Park JK, Lee KY
and Moon Y: Prognostic factors in stage IIB Non-small cell lung
cancer according to the 8th edition of TNM Staging System. Korean J
Thorac Cardiovasc Surg. 52:131–140. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Beland MD, Wasser EJ, Mayo-Smith WW and
Dupuy DE: Primary non-small cell lung cancer: Review of frequency,
location, and time of recurrence after radiofrequency ablation.
Radiology. 254:301–317. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Poch FGM, Rieder C, Ballhausen H, Knappe
V, Ritz JP, Gemeinhardt O, Kreis ME and Lehmann KS: Finding optimal
ablation parameters for multipolar radiofrequency ablation. Surg
Innov. 24:205–213. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Prud'homme C, Deschamps F, Moulin B,
Hakime A, Al-Ahmar M, Moalla S, Roux C, Teriitehau C, de Baere T
and Tselikas L: Image-guided lung metastasis ablation: A literature
review. Int J Hyperthermia. 36:37–45. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Baisi A, Raveglia F, De Simone M and
Cioffi U: Palliative role ofpercutaneous radiofrequency ablation
for severe hemoptysisin an elderly patient with inoperable lung
cancer. J Thorac Cardiovasc Surg. 140:1196–1197. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Tong Y, Yang H, Xu X, Ruan J, Liang M, Wu
J and Luo B: Effect of a hypoxic microenvironment after
radiofrequency ablation on residual hepatocellular cell migration
and invasion. Cancer Sci. 108:753–762. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Mees G, Sathekge M, Maes A and Van de
Wiele C: Radiolabelled probes targeting tumor hypoxia for
personalized medicine. Curr Pharm Des. 20:2308–2318. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wan J, Wu W, Chen Y, Kang N and Zhang R:
Insufficient radiofrequency ablation promotes the growth of
non-small cell lung cancer cells through PI3K/Akt/HIF-1α signals.
Acta Biochim Biophys Sin (Shanghai). 48:371–377. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wan J, Wu W, Huang Y, Ge W and Liu S:
Incomplete radiofrequency ablation accelerates proliferation and
angiogenesis of residual lung carcinomas via HSP70/HIF-1α. Oncol
Rep. 36:659–668. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Pinato DJ, Black JR, Trousil S, Dina RE,
Trivedi P, Mauri FA and Sharma R: Programmed cell death ligands
expression in phaeochromocytomas and paragangliomas: Relationship
with the hypoxic response, immune evasion and malignant behavior.
Oncoimmunology. 6:e13583322017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Cai FF, Xu C, Pan X, Cai L, Lin XY, Chen S
and Biskup E: Prognostic value of plasma levels of HIF-1α and
PGC-1a in breast cancer. Oncotarget. 7:77793–77806. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wan L, Huang J, Chen J, Wang R, Dong C, Lu
S and Wu X: Expression and significance of FOXP1, HIF-1α and VEGF
in renal clear cell carcinoma. J BUON. 20:188–195. 2015.PubMed/NCBI
|
|
47
|
Wachters JE, Schrijvers ML,
Slagter-Menkema L, Mastik M, de Bock GH, Langendijk JA, Kluin PM,
Schuuring E, van der Laan BF and van der Wal JE: Prognostic
significance of HIF-1α, CA-IX, and OPN in T1-T2 laryngeal carcinoma
treated with radiotherapy. Laryngoscope. 123:2154–2160. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhong H, De Marzo AM, Laughner E, Lim M,
Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL and Simons
JW: Overexpression ofhypoxia-inducible factor 1alpha in common
human cancers and their metastases. Cancer Res. 59:5830–5835.
1999.PubMed/NCBI
|
|
49
|
Kong J, Kong J, Pan B, Ke S, Dong S, Li X,
Zhou A, Zheng L and Sun WB: Insufficient radiofrequency ablation
promotes angiogenesis of residual hepatocellular carcinoma via
HIF-1α/VEGFA. PLoS One. 7:e372662012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Morine Y, Shimada M, Utsunomiya T, Imura
S, Ikemoto T, Mori H, Hanaoka J, Kanamoto M, Iwahashi S and Miyake
H: Hypoxia inducible factor expression in intrahepatic
cholangiocarcinoma. Hepatogastroenterology. 58:1439–1444. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kitajima Y and Miyazaki K: The Critical
impact of HIF-1α on gastric cancer biology. Cancers (Basel).
5:15–26. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhao X, Fu X, Blumenthal C, Wang YT,
Jenkins MW, Snyder C, Arruda M and Rollins AM: Integrated RFA/PSOCT
catheter for real-time guidance of cardiac radio-frequency
ablation. Biomed Opt Express. 9:6400–6411. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wu W, Wan J, Xia R, Huang Z, Ni J and Yang
M: Functional role of regulatory T cells in B cell lymphoma and
related mechanisms. Int J Clin Exp Pathol. 8:9133–9139.
2015.PubMed/NCBI
|
|
54
|
Bagrodia A, Krabbe LM, Gayed BA, Kapur P,
Bernstein I, Xie XJ, Wood CG, Karam JA, Weizer AZ, Raman JD, et al:
Evaluation of the prognostic significance of altered mammalian
target of rapamycin pathway biomarkers in upper tract urothelial
carcinoma. Urology. 84:1134–1140. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Karagoz B, Bilgi O, Gumus M, Erikci AA,
Sayan O, Turken O, Kandemir EG, Oztürk A and Yaylaci M:
CD8+CD28-cells and CD4+CD25+ regulatory T cells in the peripheral
blood of advanced stage lung cancer patients. Med Oncol. 27:29–33.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Ke X, Zhang S, Xu J, Liu G, Zhang L, Xie
E, Gao L, Li D, Sun R, Wang F and Pan S: Non-small-cell lung
cancer-induced immunosuppression by increased human regulatory T
cells via Foxp3 promoter demethylation. Cancer Immunol Immunother.
65:587–599. 2016. View Article : Google Scholar : PubMed/NCBI
|
